DE69739319D1 - Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe - Google Patents

Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe

Info

Publication number
DE69739319D1
DE69739319D1 DE69739319T DE69739319T DE69739319D1 DE 69739319 D1 DE69739319 D1 DE 69739319D1 DE 69739319 T DE69739319 T DE 69739319T DE 69739319 T DE69739319 T DE 69739319T DE 69739319 D1 DE69739319 D1 DE 69739319D1
Authority
DE
Germany
Prior art keywords
proteins
isoforms
pdgf
clipped
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739319T
Other languages
English (en)
Inventor
Patricia Tekamp-Olson
James Merryweather
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE69739319D1 publication Critical patent/DE69739319D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
DE69739319T 1996-12-13 1997-12-12 Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe Expired - Lifetime DE69739319D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3272096P 1996-12-13 1996-12-13

Publications (1)

Publication Number Publication Date
DE69739319D1 true DE69739319D1 (de) 2009-04-30

Family

ID=21866458

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69738768T Expired - Lifetime DE69738768D1 (de) 1996-12-13 1997-12-12 Analyse und separation von pdgf-proteinen
DE69725881T Expired - Lifetime DE69725881T2 (de) 1996-12-13 1997-12-12 Verfahren zur expression von heterologen proteinen in hefe
DE69739319T Expired - Lifetime DE69739319D1 (de) 1996-12-13 1997-12-12 Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69738768T Expired - Lifetime DE69738768D1 (de) 1996-12-13 1997-12-12 Analyse und separation von pdgf-proteinen
DE69725881T Expired - Lifetime DE69725881T2 (de) 1996-12-13 1997-12-12 Verfahren zur expression von heterologen proteinen in hefe

Country Status (9)

Country Link
US (10) US6017731A (de)
EP (4) EP1365028B1 (de)
JP (4) JP4275741B2 (de)
AT (3) ATE426030T1 (de)
AU (2) AU5794598A (de)
DE (3) DE69738768D1 (de)
ES (1) ES2306462T3 (de)
PT (1) PT948538E (de)
WO (2) WO1998025963A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486491T2 (de) 1983-04-25 2003-01-16 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US5811381A (en) * 1996-10-10 1998-09-22 Mark A. Emalfarb Cellulase compositions and methods of use
US7883872B2 (en) * 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
AU5794598A (en) * 1996-12-13 1998-07-03 Patricia Tekamp-Olson Method for expression of heterologous proteins in yeast
ES2237159T3 (es) * 1998-10-06 2005-07-16 Mark Aaron Emalfarb Sistema de transformacion en el campo de los hongos micoticos filamentosos en chrysosporium.
US20040146918A1 (en) * 2000-02-18 2004-07-29 Weiner Michael L. Hybrid nucleic acid assembly
US7166712B2 (en) * 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
US20080014594A1 (en) * 2003-01-31 2008-01-17 Kevin Hestir Lung-Expressed Polypeptides
JP2007529993A (ja) 2003-07-02 2007-11-01 シンジェンタ パーティシペーションズ アーゲー グルカナーゼ、それらをコードする核酸並びにそれらを製造及び使用する方法
DE10342794A1 (de) * 2003-09-16 2005-04-21 Basf Ag Sekretion von Proteinen aus Hefen
EP1689348B1 (de) 2003-12-05 2013-05-15 Children's Hospital Medical Center Oligosaccharid-Zusammensetzungen und ihre Verwendung bei der Behandlung von Infektionen
AU2005209926B2 (en) 2004-02-02 2007-09-06 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
EP1771205B1 (de) * 2004-06-18 2016-10-26 Ambrx, Inc. Neuartige antigen-bindende polypeptide und ihre verwendungen
AU2005327906B2 (en) * 2004-07-21 2010-05-13 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US8114841B2 (en) * 2004-10-14 2012-02-14 Biomimetic Therapeutics, Inc. Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
NZ555386A (en) 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
MX2007007591A (es) 2004-12-22 2007-07-25 Ambrx Inc Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
ATE541934T1 (de) * 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
EP2284191A3 (de) 2004-12-22 2011-07-20 Ambrx, Inc. Prozess zur Herstellung von hGH
CA2609205A1 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
AU2006267039A1 (en) * 2005-07-12 2007-01-18 Codon Devices, Inc. Compositions and methods for biocatalytic engineering
CN103103238B (zh) 2005-08-18 2016-08-10 Ambrx公司 一种在细胞中制造在特定位置处具有所选氨基酸的抗体或抗体片段多肽的方法
FR2891149B1 (fr) 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
PT1954710E (pt) * 2005-11-08 2011-06-07 Ambrx Inc Aceleradores para a modificação de aminoácidos nãonaturais e polipeptídeos de aminoácidos não-naturais
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
AU2006326404B2 (en) * 2005-12-14 2011-11-03 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1991282B1 (de) * 2006-02-09 2013-06-19 BioMimetic Therapeutics, LLC Zusammensetzungen und verfahren zur behandlung von knochen
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
ES2664229T3 (es) 2006-06-30 2018-04-18 Biomimetic Therapeutics, Llc Composiciones y métodos de biomatriz-PDGF para el tratamiento de lesiones del manguito rotador
AU2007292893B2 (en) 2006-09-08 2012-03-01 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
WO2008030613A2 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
US8106008B2 (en) 2006-11-03 2012-01-31 Biomimetic Therapeutics, Inc. Compositions and methods for arthrodetic procedures
US9862956B2 (en) 2006-12-10 2018-01-09 Danisco Us Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
WO2008073914A2 (en) 2006-12-10 2008-06-19 Dyadic International Inc. Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
BRPI0809583B1 (pt) 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CA2736661A1 (en) * 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
CN102014977B (zh) 2008-02-07 2015-09-02 生物模拟治疗有限责任公司 用于牵引成骨术的组合物和方法
CN101939443B (zh) 2008-02-08 2014-01-29 Ambrx公司 经修饰瘦素多肽和其用途
UA118536C2 (uk) 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
CN102231992B (zh) 2008-09-09 2015-05-20 生物模拟治疗公司 用于治疗肌腱和韧带损伤的血小板衍生生长因子的组合物和方法
BRPI0919403A2 (pt) 2008-09-26 2017-09-26 Ambrx Inc polipeptídeos modificados de eritropoetina animal e seus usos
ES2660000T3 (es) 2008-09-26 2018-03-20 Ambrx, Inc. Vacunas y microorganismos dependientes de la replicación de aminoácidos no naturales
US8183346B2 (en) * 2008-12-05 2012-05-22 Eli Lilly And Company Anti-ferroportin 1 monoclonal antibodies and uses thereof
WO2011087808A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
MX2012006980A (es) 2009-12-21 2012-07-17 Ambrx Inc Polipeptidos de somatotropina porcina modificados y sus usos.
MX2012009687A (es) 2010-02-22 2012-11-29 Biomimetic Therapeutics Inc Metodos y composiciones de factor de crecimiento derivado de plaquetas y métodos para el tratamiento de tendinopatías.
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
BR112013003522B1 (pt) 2010-08-17 2021-05-25 Ambrx, Inc. polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN105085652B (zh) 2014-05-16 2021-06-22 中国人民解放军军事医学科学院生物工程研究所 血小板衍生生长因子b突变体、其制备方法及用途
EP3206670A4 (de) * 2014-10-14 2018-06-20 Samuel Lynch Zusammensetzung zur behandlung von wunden
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
CN106496302B (zh) * 2015-09-08 2021-12-10 三生国健药业（上海）股份有限公司 一种用离子交换层析纯化蛋白质的方法
CN108239648B (zh) * 2016-12-26 2023-04-07 丰益(上海)生物技术研发中心有限公司 高效表达米黑根毛霉脂肪酶的方法
TW201837051A (zh) 2017-02-08 2018-10-16 美商必治妥美雅史谷比公司 包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途
CN110590930B (zh) * 2018-06-13 2023-03-31 四川好医生攀西药业有限责任公司 美洲大蠊生长因子pdgf在制备损伤修复药物中的应用
CN113015782A (zh) * 2018-11-19 2021-06-22 巴斯夫欧洲公司 用于酵母的前导序列

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359180A (en) * 1942-08-11 1944-09-26 Gen Motors Corp Dynamic balancer
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
US4801542A (en) 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
EP0487116B1 (de) * 1984-10-12 1999-12-29 ZymoGenetics, Inc. Von Blutplättchen abstammende biologisch aktive Analoga eines Wachstumsfaktors in eukaryotischen Zellen
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4769328A (en) 1984-10-12 1988-09-06 Zymogenetics Inc. Expression of biologically active PDGF analogs in yeast
US4849407A (en) * 1986-08-13 1989-07-18 Zymogenetics, Inc. Biologically active mosaic proteins
US5187263A (en) * 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
US5045633A (en) * 1985-02-25 1991-09-03 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5516896A (en) * 1985-02-25 1996-05-14 Zymogenetics, Inc. Biologically active B-chain homodimers
JPS6236183A (ja) * 1985-06-20 1987-02-17 ザ・サルク・インステイチユ−ト・バイオテクノロジ−／インダストリアル・アソシエイツ・インコ−ポレ−テツド サツカロミセス・セレビシエからのポリペプチドの発現および分泌
DE3751632T2 (de) * 1986-08-13 1996-06-13 Zymogenetics Inc Expression von biologisch-aktiven PDGF-Analogen in eukaryotischen Zellen
KR960005708B1 (ko) 1986-11-14 1996-05-01 인스티튜트 오브 몰레큘러 바이올로지, 인코오포레이티드 외상 치료 및 뼈 재생용 조성물
US5019559A (en) 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5219759A (en) * 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
CA1340772C (en) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DE3900770A1 (de) * 1989-01-12 1990-07-26 Juergen Prof Dr Hoppe Verfahren zur herstellung von pdgf-a und pdgf-aa
US5968778A (en) * 1989-01-12 1999-10-19 Jurgen Hoppe PDGF-AB, preparation process and pharmaceuticals containing them
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
DE69031218T2 (de) 1990-04-10 1997-12-11 Inst Molecular Biology Inc Wundheilung
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
DE69102651T2 (de) * 1990-07-23 1994-10-06 Zymogenetics Inc Proteaseresistenter pdgf und dessen verwendungen.
DE69123979T2 (de) * 1990-10-12 1997-04-30 Max Planck Gesellschaft Abgeänderte ribozyme
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DE4216134A1 (de) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
WO1993008825A1 (en) 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
EP0681482B1 (de) * 1993-01-22 2005-12-07 University Research Corporation Lokalisierung von therapeutischen mitteln
JP3545403B2 (ja) 1993-04-22 2004-07-21 スカイファルマ インコーポレイテッド 医薬化合物を被包しているシクロデキストリンリポソーム及びその使用法
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
DK0729351T3 (da) 1993-11-16 2000-10-16 Skyepharma Inc Vesikler med reguleret afgivelse af aktivstoffer
US5902880A (en) * 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5627053A (en) * 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
ATE386131T1 (de) * 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
IL114160A (en) * 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US6146886A (en) * 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5716824A (en) * 1995-04-20 1998-02-10 Ribozyme Pharmaceuticals, Inc. 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
AU5794598A (en) * 1996-12-13 1998-07-03 Patricia Tekamp-Olson Method for expression of heterologous proteins in yeast
US6248878B1 (en) * 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6001311A (en) * 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules

Also Published As

Publication number Publication date
PT948538E (pt) 2008-08-05
US20050124042A1 (en) 2005-06-09
JP2001518073A (ja) 2001-10-09
DE69725881T2 (de) 2004-09-09
EP0948538B1 (de) 2008-06-11
US6448382B1 (en) 2002-09-10
US20020055169A1 (en) 2002-05-09
US6312923B1 (en) 2001-11-06
JP2008031173A (ja) 2008-02-14
EP1365028A1 (de) 2003-11-26
EP0946736A1 (de) 1999-10-06
ATE398139T1 (de) 2008-07-15
AU5794598A (en) 1998-07-03
JP4275741B2 (ja) 2009-06-10
EP1365028B1 (de) 2009-03-18
US6083723A (en) 2000-07-04
US7166446B2 (en) 2007-01-23
US20030036511A1 (en) 2003-02-20
US6706496B2 (en) 2004-03-16
US7084262B2 (en) 2006-08-01
ATE426030T1 (de) 2009-04-15
US6017731A (en) 2000-01-25
US20030077831A1 (en) 2003-04-24
EP0948538A1 (de) 1999-10-13
JP2008119008A (ja) 2008-05-29
JP4341859B2 (ja) 2009-10-14
AU5465498A (en) 1998-07-03
WO1998025963A1 (en) 1998-06-18
DE69738768D1 (de) 2008-07-24
EP1935901A1 (de) 2008-06-25
DE69725881D1 (de) 2003-12-11
WO1998026080A1 (en) 1998-06-18
US6083910A (en) 2000-07-04
JP2001506497A (ja) 2001-05-22
ES2306462T3 (es) 2008-11-01
EP0946736B1 (de) 2003-10-29
US6897043B2 (en) 2005-05-24
ATE253120T1 (de) 2003-11-15
US20060252695A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
DE69739319D1 (de) Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe
RU95115239A (ru) Аналог эритропоэтина
DE69331507D1 (de) Verfahren zur Reinigung von menschlichem, rekombinantem Serumalbumin
DE173233T1 (de) Methode und mittel fuer chromatografie.
ES2035920T3 (es) Aerolizacion de agente proteico terapeutico.
BR8605129A (pt) Processo para purificacao de uma proteina atraves de cromatografia de coluna e processo para purificar fator anti-hemofilico a partir de crioprecipitado de plasma
IT8547835A0 (it) Procedimento di purificazione di proteine ossee
ATE187462T1 (de) Reinigung von alpha-l-proteinaseinhibitor mittels neuen chromatographischen trennungsbedingungen
DK0409472T3 (da) Knoglemorfogenetisk protein
NO990560L (no) Kjemisk modifiserte polypeptider
DE3177260D1 (de) Fuer plasminogen-aktivator kodierende rekombinante desoxyribonukleinsaeure und verfahren zur herstellung von plasminogen-aktivator-protein daraus.
SE9603068D0 (sv) Process for purifying a protein
ATE552891T1 (de) Kombination von sauren-proteaseenzymen und sauren pufferlösungen sowie deren verwendung
DE3684633D1 (de) Dipeptid-derivate von fettsaeure, verfahren zu ihrer herstellung, heilmittel, das sie enthaelt und anwendung.
DE3884356D1 (de) Verfahren zur Herstellung von Fremdprotein in Hefe, Rekombinant DNS, Transformant.
NO920671D0 (no) Fremgangsmaate for aktivering av rekombinante proteiner
DE69326559T2 (de) Rekombinante methode und wirt zur herstellung von xylitol
DE3683512D1 (de) Verfahren zur optischen isomerisierung von optisch aktiver aminosaeure und verfahren zur herstellung von optisch aktiver aminosaeure.
KR880701777A (ko) 재조합 dna 방법에 의해 제조된 인간의 췌장 분비 트립신 억제제와 그의 제조방법
DE59712000D1 (de) Herstellung von Carbonsäurefluoriden
DE3761373D1 (de) Verfahren zur herstellung von fluor enthaltenden alpha,beta-ungesaettigten carbonsaeuren.
DE68925918T2 (de) Methode zur Reinigung von Antithrombin-III und Antithrombin-III-Zusammensetzung enthaltend dieses Antithrombin-III
DE69533905D1 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung
DE68910036T2 (de) Luciferase-Gen und neue rekombinante DNA sowie Verfahren zur Herstellung von Luciferase.
DE69503956T2 (de) Verfahren zur Herstellung von optisch aktiver alpha-(Hydroxyphenoxy)-alkancarbonsäure und ihren Derivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition